{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:43:47Z","timestamp":1791585827378,"version":"4.3.4"},"reference-count":349,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001835","name":"Universiteit Maastricht","doi-asserted-by":"publisher","award":["015.011.033"],"award-info":[{"award-number":["015.011.033"]}],"id":[{"id":"10.13039\/501100001835","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.autrev.2022.103104","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T13:08:00Z","timestamp":1650373680000},"page":"103104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders"],"prefix":"10.1016","volume":"21","author":[{"given":"Marina","family":"Man\u00e9-Damas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Molenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ulrichts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florit","family":"Marcuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc H.","family":"De Baets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Martinez-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Losen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.autrev.2022.103104_bb0005","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2022.103104_bb0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e8497","article-title":"Myasthenia gravis","volume":"345","author":"Spillane","year":"2012","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.autrev.2022.103104_bb0015","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"issue":"15","key":"10.1016\/j.autrev.2022.103104_bb0020","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jama.1930.27120410003009c","article-title":"Report of progress on the use of ephedrine in a case of myasthenia gravis","volume":"94","author":"Edgeworth","year":"1930","journal-title":"JAMA"},{"issue":"5779","key":"10.1016\/j.autrev.2022.103104_bb0025","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S0140-6736(00)94294-6","article-title":"Treatment of myasthenia gravis with physostigmine","volume":"223","author":"Walker","year":"1934","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb0030","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1113\/jphysiol.1964.sp007495","article-title":"An electrophysiological investigation of neuro-muscular transmission in myasthenia gravis","volume":"174","author":"Elmqvist","year":"1964","journal-title":"J Physiol"},{"issue":"4109","key":"10.1016\/j.autrev.2022.103104_bb0035","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1126\/science.182.4109.293","article-title":"Neuromuscular Junction in Myasthenia Gravis: Decreased Acetylcholine Receptors","volume":"182","author":"Fambrough","year":"1973","journal-title":"Science"},{"issue":"4088","key":"10.1016\/j.autrev.2022.103104_bb0040","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1126\/science.180.4088.871","article-title":"Autoimmune Response to Acetylcholine Receptor","volume":"180","author":"Patrick","year":"1973","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.autrev.2022.103104_bb0045","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1084\/jem.141.6.1365","article-title":"Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs","volume":"141","author":"Lennon","year":"1975","journal-title":"J Exp Med"},{"issue":"4158","key":"10.1016\/j.autrev.2022.103104_bb0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1126\/science.186.4158.55","article-title":"Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors","volume":"186","author":"Almon","year":"1974","journal-title":"Science"},{"issue":"7907","key":"10.1016\/j.autrev.2022.103104_bb0055","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(75)91886-3","article-title":"Myasthenia gravis: a serum factor blocking acetylcholine receptors of the human neuromuscular junction","volume":"1","author":"Bender","year":"1975","journal-title":"Lancet."},{"issue":"11","key":"10.1016\/j.autrev.2022.103104_bb0060","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.autrev.2022.103104_bb0065","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1046\/j.1460-9568.2000.00195.x","article-title":"Different functions of fetal and adult AChR subtypes for the formation and maintenance of neuromuscular synapses revealed in \u03b5-subunit-deficient mice","volume":"12","author":"Schwarz","year":"2000","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.autrev.2022.103104_bb0070","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","article-title":"Diagnostic and clinical classification of autoimmune myasthenia gravis","volume":"48-49","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb0075","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2008.10.002","article-title":"Lrp4 is a receptor for agrin and forms a complex with MuSK","volume":"135","author":"Kim","year":"2008","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb0080","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0092-8674(00)81251-9","article-title":"The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo","volume":"85","author":"DeChiara","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2022.103104_bb0085","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/35074025","article-title":"Distinct roles of nerve and muscle in postsynaptic differentiation of the neuromuscular synapse","volume":"410","author":"Lin","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2022.103104_bb0090","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb0095","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor\u2013related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb0100","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb0105","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.autrev.2022.103104_bb0110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb0115","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J Neurol"},{"issue":"22","key":"10.1016\/j.autrev.2022.103104_bb0120","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/WNL.0000000000000478","article-title":"Anti-agrin autoantibodies in myasthenia gravis","volume":"82","author":"Gasperi","year":"2014","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.autrev.2022.103104_bb0125","doi-asserted-by":"crossref","first-page":"e975","DOI":"10.1212\/WNL.0000000000012463","article-title":"Characterization of LRP4\/agrin antibodies from a patient with myasthenia gravis","volume":"97","author":"Yu","year":"2021","journal-title":"Neurology"},{"issue":"520","key":"10.1016\/j.autrev.2022.103104_bb0130","article-title":"IgG subclasses and allotypes: From structure to effector functions","volume":"5","author":"Gestur Vidarsson","year":"2014","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb0135","doi-asserted-by":"crossref","first-page":"360","DOI":"10.4103\/IJPM.IJPM_542_16","article-title":"Age-related reference intervals for immunoglobulin levels and lymphocyte subsets in Indian children","volume":"60","author":"Narula","year":"2017","journal-title":"Indian J Pathol Microbiol"},{"issue":"5\u20136","key":"10.1016\/j.autrev.2022.103104_bb0140","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/08916930903555943","article-title":"Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction","volume":"43","author":"Gomez","year":"2010","journal-title":"Autoimmunity"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/joim.12163","article-title":"Pathogenic immune mechanisms at the neuromuscular synapse: the role of specific antibody-binding epitopes in myasthenia gravis","volume":"275","author":"Huijbers","year":"2013","journal-title":"J Intern Med"},{"issue":"9","key":"10.1016\/j.autrev.2022.103104_bb0150","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/jnnp-2012-302705","article-title":"Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis","volume":"83","author":"Masuda","year":"2012","journal-title":"J Neurol Neurosurgery Psychiatry"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb0155","first-page":"257","article-title":"Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles","volume":"49","author":"Newsom-Davis","year":"1982","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0160","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3","volume":"67","author":"R\u00f8dgaard","year":"1987","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02935610","article-title":"The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies","volume":"5","author":"Tzartos","year":"1991","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.autrev.2022.103104_bb0170","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-065X.1998.tb01190.x","article-title":"Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor","volume":"16","author":"Tzartos","year":"1998","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb0175","first-page":"245","article-title":"Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors","volume":"45","author":"Lindstrom","year":"2011","journal-title":"autoimmunity"},{"issue":"20","key":"10.1016\/j.autrev.2022.103104_bb0180","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.autrev.2022.103104_bb0185","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/eji.1830220939","article-title":"Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor","volume":"22","author":"Loutrari","year":"1992","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb0190","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1084\/jem.127.3.523","article-title":"Antigenic modulation. Loss of TL antigen from cells exposed to TL antibody. Study of the phenomenon in vitro","volume":"127","author":"Old","year":"1968","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.autrev.2022.103104_bb0195","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/brain\/awh612","article-title":"Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis","volume":"128","author":"Losen","year":"2005","journal-title":"Brain"},{"issue":"Pt 3","key":"10.1016\/j.autrev.2022.103104_bb0200","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1113\/jphysiol.2004.077685","article-title":"Increased ratio of rapsyn to ACh receptor stabilizes postsynaptic receptors at the mouse neuromuscular synapse","volume":"562","author":"Gerv\u00e1sio","year":"2005","journal-title":"J Physiol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb0205","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1084\/jem.147.4.973","article-title":"Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis","volume":"147","author":"Lennon","year":"1978","journal-title":"J Exp Med"},{"issue":"6176","key":"10.1016\/j.autrev.2022.103104_bb0210","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.1248943","article-title":"Complement is activated by IgG hexamers assembled at the cell surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science (New York, NY)"},{"issue":"5","key":"10.1016\/j.autrev.2022.103104_bb0215","first-page":"267","article-title":"Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations","volume":"52","author":"Engel","year":"1977","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"10.1016\/j.autrev.2022.103104_bb0220","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.autrev.2013.03.003","article-title":"Complement associated pathogenic mechanisms in myasthenia gravis","volume":"12","author":"T\u00fcz\u00fcn","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb0225","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00005072-198003000-00005","article-title":"Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis","volume":"39","author":"Sahashi","year":"1980","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0230","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0165-5728(96)00144-0","article-title":"Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis","volume":"71","author":"Piddlesden","year":"1996","journal-title":"J Neuroimmunol"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2022.103104_bb0235","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0165-5728(97)00016-7","article-title":"Macrophage infiltration at the neuromuscular junction does not contribute to AChR loss and age-related resistance to EAMG","volume":"75","author":"Hoedemaekers","year":"1997","journal-title":"J Neuroimmunol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103104_bb0240","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1212\/WNL.43.6.1167","article-title":"Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients","volume":"43","author":"Nakano","year":"1993","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0245","first-page":"27","article-title":"Immune complexes in myasthenia gravis","volume":"5","author":"Barkas","year":"1981","journal-title":"J Clin Lab Immunol"},{"issue":"7981","key":"10.1016\/j.autrev.2022.103104_bb0250","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0140-6736(76)92644-1","article-title":"Immune complexes in myasthenia gravis","volume":"308","author":"Casali","year":"1976","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.autrev.2022.103104_bb0255","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1161\/CIRCULATIONAHA.108.771170","article-title":"Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury","volume":"120","author":"Mayadas","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2022.103104_bb0260","series-title":"Acetylcholine in intercostal muscle from myasthenia gravis patients and in rat diaphragm after blockade of acetylcholine receptors, in progress in brain research","first-page":"449","author":"Molenaar","year":"1979"},{"key":"10.1016\/j.autrev.2022.103104_bb0265","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1113\/jphysiol.1992.sp019429","article-title":"Adaptation of quantal content to decreased postsynaptic sensitivity at single endplates in alpha-bungarotoxin-treated rats","volume":"458","author":"Plomp","year":"1992","journal-title":"J Physiol"},{"issue":"5","key":"10.1016\/j.autrev.2022.103104_bb0270","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ana.410370513","article-title":"Acetylcholine release in myasthenia gravis: Regulation at single end-plate level","volume":"37","author":"Plomp","year":"1995","journal-title":"Ann Neurol"},{"issue":"5654","key":"10.1016\/j.autrev.2022.103104_bb0275","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/272641a0","article-title":"Alpha-Bungarotoxin enhances transmitter \u201creleased\u201d at the neuromuscular junction","volume":"272","author":"Miledi","year":"1978","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0280","doi-asserted-by":"crossref","first-page":"68","DOI":"10.14336\/AD.2015.0826","article-title":"Effects of use and disuse on non-paralyzed and paralyzed skeletal muscles","volume":"7","author":"Dolbow","year":"2016","journal-title":"Aging Dis"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb0285","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/jnnp.35.3.311","article-title":"Neurogenic muscle atrophy in myasthenia gravis","volume":"35","author":"Brownell","year":"1972","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.autrev.2022.103104_bb0290","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jocn.2011.09.022","article-title":"AchR-positive myasthenia gravis with MRI evidence of early muscle atrophy","volume":"19","author":"Zouvelou","year":"2012","journal-title":"J Clin Neurosci"},{"issue":"10","key":"10.1016\/j.autrev.2022.103104_bb0295","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1016\/j.ajpath.2016.05.025","article-title":"Silencing of Dok-7 in adult rat muscle increases susceptibility to passive transfer myasthenia gravis","volume":"186","author":"Gomez","year":"2016","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0300","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.nbd.2009.03.008","article-title":"Silencing rapsyn in vivo decreases acetylcholine receptors and augments sodium channels and secondary postsynaptic membrane folding","volume":"35","author":"Mart\u00ednez-Mart\u00ednez","year":"2009","journal-title":"Neurobiol Dis"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb0305","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ana.410440412","article-title":"Acquired slow\u2013channel syndrome: a form of myasthenia gravis with prolonged open time of the acetylcholine receptor channel","volume":"44","author":"Wintzen","year":"1998","journal-title":"Ann Neurol"},{"issue":"13","key":"10.1016\/j.autrev.2022.103104_bb0310","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1056\/NEJM198209233071301","article-title":"Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis","volume":"307","author":"Drachman","year":"1982","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.autrev.2022.103104_bb0315","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1073\/pnas.80.13.4089","article-title":"Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia","volume":"80","author":"Richman, C.M.G.A.D.P","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.autrev.2022.103104_bb0320","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/clinchem\/39.10.2053","article-title":"Detection and characterization of blocking-type anti-acetylcholine receptor antibodies in sera from patients with myasthenia gravis","volume":"39","author":"Hara","year":"1993","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0325","doi-asserted-by":"crossref","first-page":"14426","DOI":"10.1038\/s41598-017-14350-8","article-title":"Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient","volume":"7","author":"Saxena","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0330","first-page":"130","article-title":"Protective effect of myasthenic immunoglobulins against the lethal toxicity of alpha bungarotoxin","volume":"68","author":"Vernet-der Garabedian","year":"1987","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2022.103104_bb0335","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1212\/WNL.33.10.1316","article-title":"Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity","volume":"33","author":"Besinger","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2022.103104_bb0340","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients","volume":"77","author":"Koneczny","year":"2017","journal-title":"J Autoimmun"},{"issue":"5844","key":"10.1016\/j.autrev.2022.103104_bb0345","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic fab arm exchange","volume":"317","author":"van der Neut Kolfschoten","year":"2007","journal-title":"Science"},{"issue":"51","key":"10.1016\/j.autrev.2022.103104_bb0350","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb0355","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/brain\/aws025","article-title":"Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice","volume":"135","author":"Klooster","year":"2012","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.autrev.2022.103104_bb0360","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1172\/JCI66039","article-title":"Antibodies against low-density lipoprotein receptor\u2013related protein 4 induce myasthenia gravis","volume":"123","author":"Shen","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2022.103104_bb0365","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nri1707","article-title":"Central tolerance: learning self-control in the thymus","volume":"5","author":"Hogquist","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb0370","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ana.410220205","article-title":"Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study","volume":"22","author":"Schluep","year":"1987","journal-title":"Ann Neurol"},{"issue":"7156","key":"10.1016\/j.autrev.2022.103104_bb0375","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/nature06066","article-title":"An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus","volume":"448","author":"Giraud","year":"2007","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.autrev.2022.103104_bb0380","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.celrep.2018.01.015","article-title":"Age-associated decline in thymic B cell expression of aire and aire-dependent self-antigens","volume":"22","author":"Cepeda","year":"2018","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb0385","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2249.2007.03442.x","article-title":"Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas","volume":"149","author":"Scarpino","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2022.103104_bb0390","first-page":"203","article-title":"Cell proliferation in the bone marrow, thymus and spleen of mice studied by continuous, in oivo bromodeoxycytidine labelling and flow cytometric analysis","volume":"22","author":"Jones, T.L.C.a.I.M","year":"1989","journal-title":"Cell Tissue Kinet"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb0395","first-page":"514","article-title":"The survival and turnover of mature and immature CD8 T cells","volume":"84","author":"McDonagh","year":"1995","journal-title":"Immunology"},{"issue":"9, Supplement 2","key":"10.1016\/j.autrev.2022.103104_bb0400","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1097\/JTO.0000000000000299","article-title":"Alterations of the immune system in thymic malignancies","volume":"9","author":"Weksler","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.autrev.2022.103104_bb0405","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-3083.1985.tb01916.x","article-title":"The involution of the ageing human thymic epithelium is independent of puberty","volume":"22","author":"Steinmann","year":"1985","journal-title":"Scand J Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb0410","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/mus.22103","article-title":"The thymus in myasthenia gravis: Site of \u201cinnate autoimmunity\u201d?","volume":"44","author":"Cavalcante","year":"2011","journal-title":"Muscle Nerve"},{"issue":"12","key":"10.1016\/j.autrev.2022.103104_bb0415","doi-asserted-by":"crossref","first-page":"980","DOI":"10.12998\/wjcc.v3.i12.980","article-title":"Myasthenia gravis and thymic neoplasms: A brief review","volume":"3","author":"Kumar","year":"2015","journal-title":"World J Clin Cases"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb0420","first-page":"527","article-title":"Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia","volume":"57","author":"Mygland","year":"2000","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1016\/j.autrev.2022.103104_bb0425","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1002\/1097-0142(19871201)60:11<2727::AID-CNCR2820601125>3.0.CO;2-D","article-title":"Thymoma. A clinicopathologic review","volume":"60","author":"Lewis","year":"1987","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0430","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1749-6632.1993.tb22869.x","article-title":"The pathological basis of thymoma-associated myasthenia gravis","volume":"681","author":"M\u00fcller-Hermelink","year":"1993","journal-title":"Ann N Y Acad Sci"},{"issue":"Sullp 2","key":"10.1016\/j.autrev.2022.103104_bb0435","first-page":"5","article-title":"M.A., Pathological aspects of malignant and benign thymic disorders","volume":"31","author":"M\u00fcller-Hermelink","year":"1999","journal-title":"Ann Med"},{"issue":"10","key":"10.1016\/j.autrev.2022.103104_bb0440","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/jnnp.52.10.1121","article-title":"The natural course of myasthenia gravis: a long term follow up study","volume":"52","author":"Oosterhuis","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0445","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s00415-004-0278-6","article-title":"Myasthenia gravis: changes observedin a 30-years retrospective clinical study of a hospital-basedpopulation","volume":"251","author":"Potagas","year":"2004","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.autrev.2022.103104_bb0450","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.1999.17.7.2280","article-title":"Thymoma: State of the art","volume":"17","author":"Thomas","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.autrev.2022.103104_bb0455","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00001622-200009000-00007","article-title":"Thymoma","volume":"12","author":"M\u00fcller-Hermelink","year":"2000","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.autrev.2022.103104_bb0460","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lungcan.2020.12.010","article-title":"Subclinical myasthenia gravis in thymomas","volume":"152","author":"Marcuse","year":"2021","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0465","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/nyas.13519","article-title":"Thymus involvement in early-onset myasthenia gravis","volume":"1412","author":"Cron","year":"2018","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0470","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s12016-016-8558-3","article-title":"Thymic germinal centers and corticosteroids in myasthenia gravis: an immunopathological study in 1035 cases and a critical review","volume":"52","author":"Truffault","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2022.103104_bb0475","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1749-6632.1987.tb51282.x","article-title":"The role of the thymus in myasthenia gravis: immunohistological and immunological studies in 115 cases","volume":"550","author":"Berrih-Aknin","year":"1987","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"10.1016\/j.autrev.2022.103104_bb0480","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3109\/08916934.2012.665524","article-title":"Germinal center B-cells","volume":"45","author":"Hamel","year":"2012","journal-title":"Autoimmunity"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb0485","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG","volume":"57","author":"Leite","year":"2005","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb0490","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1212\/01.WNL.0000150587.71497.B6","article-title":"Thymus changes in anti-MuSK-positive and -negative myasthenia gravis","volume":"64","author":"Lauriola","year":"2005","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0495","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.autrev.2018.07.011","article-title":"Characterization of the thymus in Lrp4 myasthenia gravis: four cases","volume":"18","author":"Koneczny","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0500","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jneuroim.2007.07.007","article-title":"Heterogeneity of immunopathological features of AChR\/MuSK autoantibody-negative myasthenia gravis","volume":"189","author":"Hayashi","year":"2007","journal-title":"J Neuroimmunol"},{"issue":"10","key":"10.1016\/j.autrev.2022.103104_bb0505","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/11593300-000000000-00000","article-title":"Treatment of myasthenia gravis: focus on pyridostigmine","volume":"31","author":"Maggi","year":"2011","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.autrev.2022.103104_bb0510","article-title":"Acetylcholinesterase inhibitor treatment for myasthenia gravis","volume":"10","author":"Mehndiratta","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.autrev.2022.103104_bb0515","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/11593300-000000000-00000","article-title":"Treatment of myasthenia gravis: focus on pyridostigmine","volume":"13","author":"Maggi","year":"2011","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.autrev.2022.103104_bb0520","article-title":"Immunosuppressive agents for myasthenia gravis","volume":"4","author":"Hart","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"4457","key":"10.1016\/j.autrev.2022.103104_bb0525","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/175594b0","article-title":"Neuromuscular block caused by acetylcholine","volume":"175","author":"Thesleff","year":"1955","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2022.103104_bb0530","first-page":"728983","article-title":"New acetylcholinesterase inhibitors for Alzheimer's disease","volume":"2012","author":"Mehta","year":"2012","journal-title":"Int J Alzheimer's Dis"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb0535","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1046\/j.1365-2125.1999.00026.x","article-title":"Acetylcholinesterase inhibitors in Alzheimer's disease","volume":"48","author":"McGleenon","year":"1999","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb0540","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2022.103104_bb0545","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0550","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000116785","article-title":"Long-term results of corticosteroid therapy in patients with myasthenia gravis","volume":"32","author":"Evoli","year":"1992","journal-title":"Eur Neurol"},{"issue":"8","key":"10.1016\/j.autrev.2022.103104_bb0555","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/ene.13040","article-title":"GR gene polymorphism is associated with inter-subject variability in response to glucocorticoids in patients with myasthenia gravis","volume":"23","author":"Xie","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2022.103104_bb0560","series-title":"Edinburgh","first-page":"264","article-title":"Myasthenia gravis","author":"Oosterhuis","year":"1984"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb0565","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0002-9343(94)90131-7","article-title":"Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events","volume":"96","author":"Saag","year":"1994","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.autrev.2022.103104_bb0570","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2022.103104_bb0575","series-title":"Azathioprine, Azathioprine Sodium","author":"Pharmacists, A.S.o.H.-S","year":"2012"},{"key":"10.1016\/j.autrev.2022.103104_bb0580","series-title":"Vienna: \u00d6sterreichischer Apothekerverlag., ed. Austria-Codex","first-page":"4130","author":"Jasek","year":"2007"},{"issue":"12","key":"10.1016\/j.autrev.2022.103104_bb0585","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1212\/WNL.0000000000002405","article-title":"Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study","volume":"86","author":"Oskarsson","year":"2016","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.autrev.2022.103104_bb0590","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.autrev.2022.103104_bb0595","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients","volume":"41","author":"Hehir","year":"2010","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0600","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2377-11-97","article-title":"A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0605","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.autrev.2022.103104_bb0610","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.4049\/jimmunol.1390055","article-title":"Calcineurin inhibitors: 40 years later, can\u2019t live without \u2026","volume":"191","author":"Azzi","year":"2013","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2022.103104_bb0615","first-page":"4760","article-title":"Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location","volume":"13","author":"Bram","year":"1993","journal-title":"Mol Cell Biol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb0620","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0404.2005.00378.x","article-title":"Cyclosporine in the treatment of myasthenia gravis","volume":"111","author":"Lavrnic","year":"2005","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0625","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A clinical therapeutic trial of cyclosporine in myasthenia gravisa","volume":"681","author":"Tindall","year":"1993","journal-title":"Ann N Y Acad Sci"},{"issue":"5-6","key":"10.1016\/j.autrev.2022.103104_bb0630","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/08916930903518107","article-title":"Immunosuppressive therapies in myasthenia gravis","volume":"43","author":"Sanders","year":"2010","journal-title":"Autoimmunity"},{"issue":"5","key":"10.1016\/j.autrev.2022.103104_bb0635","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/ndt\/gfh739","article-title":"Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results","volume":"20","author":"Kr\u00e4mer","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.autrev.2022.103104_bb0640","doi-asserted-by":"crossref","first-page":"511","DOI":"10.7326\/0003-4819-132-6-200003210-00024","article-title":"FK506-induced autoimmune diabetes","volume":"132","author":"Kawai","year":"2000","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0645","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mus.10018","article-title":"Successful treatment of myasthenia gravis with tacrolimus","volume":"25","author":"Evoli","year":"2002","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb0650","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/1756285615571873","article-title":"The emerging role of tacrolimus in myasthenia gravis","volume":"8","author":"Cruz","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"10.1016\/j.autrev.2022.103104_bb0655","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","article-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"J Neurol Neurosurgery Psychiatry"},{"issue":"11","key":"10.1016\/j.autrev.2022.103104_bb0660","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jocn.2014.03.019","article-title":"Long-term efficacy and limitations of cyclophosphamide in myasthenia gravis","volume":"21","author":"Nagappa","year":"2014","journal-title":"J Clin Neurosci"},{"issue":"6","key":"10.1016\/j.autrev.2022.103104_bb0665","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.08880813","article-title":"Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy","volume":"9","author":"van den Brand","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.autrev.2022.103104_bb0670","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jnci\/87.7.524","article-title":"Bladder and kidney cancer following cyclophosphamide therapy for non-hodgkin's lymphoma","volume":"87","author":"Travis","year":"1995","journal-title":"JNCI"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb0675","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00281-011-0245-0","article-title":"Immunomodulatory effects of cyclophosphamide and implementations for vaccine design","volume":"33","author":"Zitvogel","year":"2011","journal-title":"Semin Immunopathol"},{"issue":"11","key":"10.1016\/j.autrev.2022.103104_bb0680","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1084\/jem.20040168","article-title":"Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB\/W mice","volume":"199","author":"Hoyer","year":"2004","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb0685","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaut.2012.05.010","article-title":"Bone marrow of NZB\/W mice is the major site for plasma cells resistant to dexamethasone and cyclophosphamide: Implications for the treatment of autoimmunity","volume":"39","author":"Mumtaz","year":"2012","journal-title":"J Autoimmun"},{"issue":"11","key":"10.1016\/j.autrev.2022.103104_bb0690","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1084\/jem.20040719","article-title":"Targeting plasma cells in autoimmune diseases","volume":"199","author":"Tarlinton","year":"2004","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0695","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13075-015-0603-8","article-title":"Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus","volume":"17","author":"Fassbinder","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2022.103104_bb0700","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1212\/WNL.31.1.32","article-title":"Stable remissions in myasthenia gravis","volume":"1","author":"Perez","year":"1981","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0705","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mus.10133","article-title":"Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis","volume":"26","author":"Gustavo De Feo","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2022.103104_bb0710","first-page":"43","article-title":"Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide","author":"Flachenecker","year":"1998","journal-title":"Transfus Sci"},{"issue":"5","key":"10.1016\/j.autrev.2022.103104_bb0715","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/jnnp.2003.019232","article-title":"High dose cyclophosphamide for severe refractory myasthenia gravis","volume":"75","author":"Gladstone","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2022.103104_bb0720","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1196\/annals.1405.033","article-title":"Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis","volume":"1132","author":"Drachman","year":"2008","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0725","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.10400","article-title":"Treatment of refractory myasthenia: \u201cRebooting\u201d with high-dose cyclophosphamide","volume":"53","author":"Drachman","year":"2003","journal-title":"Ann Neurol"},{"issue":"18","key":"10.1016\/j.autrev.2022.103104_bb0730","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jama.1941.02820440037009","article-title":"The treatment of Myashtenia Gravis bt removel of the thymus gland: Preliminary report","volume":"117","author":"Blalock","year":"1941","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0735","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-510X(03)00087-X","article-title":"Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients: remission after 6 years of follow-up","volume":"212","author":"Mantegazza","year":"2003","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2022.103104_bb0740","doi-asserted-by":"crossref","first-page":"113","DOI":"10.21037\/jovs.2017.06.13","article-title":"The results of video-assisted thoracoscopic thymectomies in Saint Petersburg, Russia: 20-year of experience","volume":"3","author":"Yablonsky","year":"2017","journal-title":"J Visual Surgery"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb0745","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0022-510X(91)90260-E","article-title":"Prognosis of myasthenia gravis: A multicenter follow-up study of 844 patients","volume":"106","author":"Beghi","year":"1991","journal-title":"J Neurol Sci"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb0750","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.athoracsur.2010.01.038","article-title":"Assessment of robotic thymectomy using the myasthenia gravis foundation of America guidelines","volume":"89","author":"Goldstein","year":"2010","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb0755","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.surg.2008.11.009","article-title":"Thymectomy is more effective than conservative treatment for myasthenia gravis regarding outcome and clinical improvement","volume":"145","author":"Bachmann","year":"2009","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.autrev.2022.103104_bb0760","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb0765","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial","volume":"18","author":"Wolfe","year":"2019","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0770","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5152\/eurasianjmed.2017.17009","article-title":"Thymectomy in Myasthenia Gravis","volume":"49","author":"Aydin","year":"2017","journal-title":"Eurasian J Med"},{"key":"10.1016\/j.autrev.2022.103104_bb0775","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jneuroim.2017.01.005","article-title":"Effect of thymectomy for thymic atrophy in myasthenia gravis: A retrospective study on 93 patients","volume":"305","author":"Nakahara","year":"2017","journal-title":"J Neuroimmunol"},{"issue":"21","key":"10.1016\/j.autrev.2022.103104_bb0780","first-page":"01832","article-title":"Robotic thymectomy for thymomas: a retrospective follow-up study in the Netherlands","volume":"S0003-4975","author":"Marcuse","year":"2021","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb0785","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jtcvs.2010.11.042","article-title":"Comparison of robotic and nonrobotic thoracoscopic thymectomy: a cohort study","volume":"141","author":"Ruckert","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"10.1016\/j.autrev.2022.103104_bb0790","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.nrl.0000240856.03505.b5","article-title":"Ocular myasthenia: diagnosis, treatment, and pathogenesis","volume":"12","author":"Kusner","year":"2006","journal-title":"Neurologist"},{"issue":"5","key":"10.1016\/j.autrev.2022.103104_bb0795","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ana.410140504","article-title":"Prognosis of ocular myasthenia","volume":"14","author":"Bever","year":"1983","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb0800","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1067\/mtc.2001.116191","article-title":"Thymectomy in the treatment of ocular myasthenia gravis","volume":"122","author":"Roberts","year":"2001","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb0805","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/jnnp.48.4.332","article-title":"Thymectomy in myasthenia with pure ocular symptoms","volume":"48","author":"Schumm","year":"1985","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0810","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2012.06767.x","article-title":"IVIG and PLEX in the treatment of myasthenia gravis","volume":"1275","author":"Bril","year":"2012","journal-title":"Ann N Y Acad Sci"},{"issue":"23","key":"10.1016\/j.autrev.2022.103104_bb0815","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"issue":"1 Supplement","key":"10.1016\/j.autrev.2022.103104_bb0820","article-title":"Costs and charges for plasma exchange (PLEX) versus intravenous immunoglobulin (IVIg) in the treatment of neuromuscular disease (PD6.008)","volume":"78","author":"Robinson","year":"2012","journal-title":"Neurology"},{"issue":"12 suppl 6","key":"10.1016\/j.autrev.2022.103104_bb0825","first-page":"S13","article-title":"Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies","volume":"59","author":"Dalakas","year":"2002","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb0830","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology--mode of action and clinical efficacy","volume":"11","author":"L\u00fcnemann","year":"2015","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"10.1016\/j.autrev.2022.103104_bb0835","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1586\/1744666X.2014.971757","article-title":"Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes","volume":"10","author":"Alabdali","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb0840","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM199901213400311","article-title":"Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases","volume":"340","author":"Yu","year":"1999","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2022.103104_bb0845","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1006\/jaut.1993.1057","article-title":"Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg","volume":"6","author":"Masson","year":"1993","journal-title":"J Autoimmun"},{"issue":"1299","key":"10.1016\/j.autrev.2022.103104_bb0850","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0855","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1196\/annals.1348.004","article-title":"Neuromuscular therapeutics by RNA-targeted suppression of ACHE gene expression","volume":"1082","author":"Dori","year":"2006","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"10.1016\/j.autrev.2022.103104_bb0860","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1212\/01.wnl.0000267884.39468.7a","article-title":"Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase","volume":"69","author":"Argov","year":"2007","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb0865","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nm.2618","article-title":"Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases","volume":"18","author":"Russell","year":"2012","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb0870","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s13311-015-0345-y","article-title":"A double-blinded, randomized, placebo-controlled trial to evaluate efficacy, safety, and tolerability of single doses of tirasemtiv in patients with acetylcholine receptor-binding antibody-positive myasthenia gravis","volume":"12","author":"Sanders","year":"2015","journal-title":"Neurotherap"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0875","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0014-2999(80)90378-7","article-title":"Potency of 3,4-Diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes","volume":"61","author":"Molg\u00f3","year":"1980","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb0880","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0006-3495(78)85503-9","article-title":"3,4-diaminopyridine. A potent new potassium channel blocker","volume":"22","author":"Kirsch","year":"1978","journal-title":"Biophys J"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0885","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0022-3565(25)22023-7","article-title":"Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction","volume":"227","author":"Thomsen","year":"1983","journal-title":"J Pharmacol Exp Therap"},{"issue":"5","key":"10.1016\/j.autrev.2022.103104_bb0890","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/mus.25070","article-title":"Amifampridine phosphate (Firdapse\u00ae) is effective and safe in a phase 3 clinical trial in LEMS","volume":"53","author":"Oh","year":"2016","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.autrev.2022.103104_bb0895","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1586\/eci.10.57","article-title":"3,4-diaminopyridine for the treatment of Lambert\u2013Eaton myasthenic syndrome","volume":"6","author":"Wirtz","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2022.103104_bb0900","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1113\/jphysiol.2013.251827","article-title":"Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody","volume":"591","author":"Morsch","year":"2013","journal-title":"J Physiol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb0905","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13690","article-title":"Chloride channel inhibition improves neuromuscular function under conditions mimicking neuromuscular disorders","volume":"233","author":"Pedersen","year":"2021","journal-title":"Acta Physiol (Oxf)"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb0910","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1046\/j.1526-0968.2000.004002124.x","article-title":"Development of a specific immunoadsorbent containing immobilized synthetic peptide of acetylcholine receptor for treatment of myasthenia gravis","volume":"4","author":"Nakaji","year":"2000","journal-title":"Ther Apher"},{"key":"10.1016\/j.autrev.2022.103104_bb0915","first-page":"61","article-title":"Anti-acetylcholine receptor blocking antibody is specifically adsorbed on plasma adsorber MG50 in the treatment of myasthenia gravis","volume":"14","author":"Ide","year":"1995","journal-title":"Jpn JApheresis"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0920","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1526-0968.2003.00008.x","article-title":"Adsorption column for myasthenia gravis treatment: MedisorbaMG-50","volume":"7","author":"Nakaji","year":"2003","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.autrev.2022.103104_bb0925","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijbiomac.2013.11.003","article-title":"Expression of human AChR extracellular domain mutants with improved characteristics","volume":"63","author":"Lazaridis","year":"2014","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.autrev.2022.103104_bb0930","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jneuroim.2014.12.001","article-title":"Specific adsorbents for myasthenia gravis autoantibodies using mutants of the muscle nicotinic acetylcholine receptor extracellular domains","volume":"278","author":"Lazaridis","year":"2015","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2022.103104_bb0935","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jneuroim.2017.09.001","article-title":"Specific removal of autoantibodies by extracorporeal immunoadsorption ameliorates experimental autoimmune myasthenia gravis","volume":"312","author":"Lazaridis","year":"2017","journal-title":"J Neuroimmunol"},{"issue":"9","key":"10.1016\/j.autrev.2022.103104_bb0940","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/jnnp.43.9.836","article-title":"Passively transferred myasthenia gravis: protection of mouse endplates by Fab fragments from human myasthenic IgG","volume":"43","author":"Toyka","year":"1980","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.autrev.2022.103104_bb0945","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/0896-8411(89)90004-8","article-title":"Fab fragments of monoclonal antibodies protect the human acetylcholine receptor against antigenic modulation caused by myasthenic sera","volume":"2","author":"Sophianos","year":"1989","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb0950","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.4049\/jimmunol.158.4.1919","article-title":"Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies","volume":"158","author":"Graus","year":"1997","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb0955","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0165-5728(99)00259-3","article-title":"Prevention of passively transferred experimental autoimmune myasthenia gravis by Fab fragments of monoclonal antibodies directed against the main immunogenic region of the acetylcholine receptor","volume":"104","author":"Papanastasiou","year":"2000","journal-title":"J Neuroimmunol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb0960","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/(SICI)1521-4141(199802)28:02<616::AID-IMMU616>3.0.CO;2-I","article-title":"Modulation of the anti-acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor","volume":"28","author":"Barchan","year":"1998","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0965","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1749-6632.1998.tb10962.x","article-title":"Antibody effector mechanisms in myasthenia gravis: The complement hypothesisa","volume":"841","author":"Richman","year":"1998","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb0970","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/mus.880090404","article-title":"Effector mechanisms in myasthenia gravis: end-plate function after passive transfer of IgG, Fab, and F(ab\u2032)2 hybrid molecules","volume":"9","author":"Sterz","year":"1986","journal-title":"Muscle Nerve"},{"issue":"44","key":"10.1016\/j.autrev.2022.103104_bb0975","doi-asserted-by":"crossref","first-page":"13898","DOI":"10.1523\/JNEUROSCI.2833-09.2009","article-title":"Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity","volume":"29","author":"Luo","year":"2009","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0980","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/s41598-017-01019-5","article-title":"Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys","volume":"7","author":"Losen","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb1140","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jneuroim.2006.10.014","article-title":"Pros and cons of treating murine myasthenia gravis with anti-C1q antibody","volume":"182","author":"T\u00fcz\u00fcn","year":"2007","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2022.103104_bb1145","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaut.2013.01.003","article-title":"Complement C2 siRNA mediated therapy of myasthenia gravis in mice","volume":"42","author":"Huda","year":"2013","journal-title":"J Autoimmun"},{"issue":"14","key":"10.1016\/j.autrev.2022.103104_bb1095","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.molimm.2011.06.367","article-title":"Complement depletion with humanized cobra venom factor (CVF) improves the severity of experimental autoimmune myasthenia gravis (EAMG)","volume":"48","author":"Huda","year":"2011","journal-title":"Mol Immunol"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2022.103104_bb1150","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0165-5728(96)00144-0","article-title":"Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis","volume":"71","author":"Piddlesden","year":"1996","journal-title":"J Neuroimmunol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb1155","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.molimm.2007.06.144","article-title":"Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivo","volume":"45","author":"Hepburn","year":"2008","journal-title":"Mol Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb1045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ana.21536","article-title":"Novel complement inhibitor limits severity of experimentally myasthenia gravis","volume":"65","author":"Soltys","year":"2009","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1016\/j.autrev.2022.103104_bb1050","doi-asserted-by":"crossref","first-page":"8292","DOI":"10.1074\/jbc.M609858200","article-title":"In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick Ornithodoros moubata","volume":"282","author":"Hepburn","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2022.103104_bb1160","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.omtm.2019.04.009","article-title":"Investigational RNAi therapeutic targeting C5 is efficacious in pre-clinical models of myasthenia gravis","volume":"13","author":"Kusner","year":"2019","journal-title":"Mol Therap Methods Clin Develop"},{"issue":"12","key":"10.1016\/j.autrev.2022.103104_bb1170","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.4049\/jimmunol.179.12.8562","article-title":"Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis","volume":"179","author":"Zhou","year":"2007","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2022.103104_bb1175","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.4049\/jimmunol.142.8.2654","article-title":"Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6","volume":"142","author":"Biesecker","year":"1989","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb1180","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4049\/jimmunol.1900801","article-title":"Requirement of complement C6 for intact innate immune responses in mice","volume":"205","author":"Fattahi","year":"2020","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2022.103104_bb1135","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/mus.24057","article-title":"Targeting therapy to the neuromuscular junction: proof of concept","volume":"49","author":"Kusner","year":"2014","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb0985","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2125.2009.03491.x","article-title":"Eculizumab","volume":"68","author":"Dubois","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.autrev.2022.103104_bb0990","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood-2016-08-732800","article-title":"Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation","volume":"129","author":"Harder","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb0995","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"issue":"12","key":"10.1016\/j.autrev.2022.103104_bb1000","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb1005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb1010","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40265-019-01068-2","article-title":"Ravulizumab: first global approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.autrev.2022.103104_bb1015","series-title":"ULTOMIRIS\u2122 (Ravulizumab-cwvz): US Prescribing Information. 2018., A. Pharmaceuticals, Editor","author":"Alexion","year":"2019"},{"key":"10.1016\/j.autrev.2022.103104_bb1020","series-title":"Comprehensive positive phase 3 data For Alexion\u2019s ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria presented at American Society Of Hematology (ASH) annual meeting and published in Blood A. Pharmaceuticals, Editor","author":"Alexion","year":"2018"},{"key":"10.1016\/j.autrev.2022.103104_bb1025","series-title":"Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS\u00ae (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG), I. BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Editor","author":"Alexion","year":"2021"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb1030","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.4049\/jimmunol.174.4.2084","article-title":"Complement inhibitor of C5 activation from the Soft Tick <em>Ornithodoros moubata<\/em>","volume":"174","author":"Nunn","year":"2005","journal-title":"J Immunol"},{"issue":"16","key":"10.1016\/j.autrev.2022.103104_bb1035","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1182\/bloodadvances.2016002832","article-title":"Use of the complement inhibitor Coversin to treat HSCT-associated TMA","volume":"1","author":"Goodship","year":"2017","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.autrev.2022.103104_bb1040","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2022.103104_bb1055","series-title":"R Pharmaceuticals, Editor","article-title":"Ra Pharmaceuticals announces positive top-line data from phase 2 trial of zilucoplan in patients with generalized myasthenia gravis","author":"RA","year":"2018"},{"issue":"23","key":"10.1016\/j.autrev.2022.103104_bb1060","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1182\/blood.V126.23.939.939","article-title":"Preclinical evaluation of RA101495, a potent cyclic peptide inhibitor of C5 for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"126","author":"Ricardo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2022.103104_bb1065","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/ITT.S261414","article-title":"Complement inhibition for the treatment of myasthenia gravis","volume":"9","author":"Mantegazza","year":"2020","journal-title":"ImmunoTargets Therapy"},{"issue":"5","key":"10.1016\/j.autrev.2022.103104_bb1070","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2022.103104_bb1075","series-title":"UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results, U.s.G. Corporate, Editor","author":"UCB","year":"2022"},{"issue":"5","key":"10.1016\/j.autrev.2022.103104_bb1080","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/ajt.13168","article-title":"Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year","volume":"15","author":"Cornell","year":"2015","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.autrev.2022.103104_bb1085","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/tri.12396","article-title":"Antibody-mediated rejection despite inhibition of terminal complement","volume":"27","author":"Bentall","year":"2014","journal-title":"Transpl Int"},{"issue":"28","key":"10.1016\/j.autrev.2022.103104_bb1090","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.2174\/138161207782023748","article-title":"Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion","volume":"13","author":"Vogel","year":"2007","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.autrev.2022.103104_bb1100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.712572","article-title":"Complement factor D as a strategic target for regulating the alternative complement pathway","volume":"12","author":"Barratt","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb1105","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/imr.12392","article-title":"Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation","volume":"270","author":"Igawa","year":"2016","journal-title":"Immunol Rev"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb1110","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jaci.2020.08.028","article-title":"ARGX-117, a therapeutic complement inhibiting antibody targeting C2","volume":"147","author":"Van de Walle","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2022.103104_bb1115","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.molimm.2018.06.005","article-title":"Tissue-targeted complement therapeutics","volume":"102","author":"Tomlinson","year":"2018","journal-title":"Mol Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2022.103104_bb1120","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1002\/art.34430","article-title":"Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5","volume":"64","author":"Macor","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb1125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058696","article-title":"Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5","volume":"8","author":"Durigutto","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2022.103104_bb1130","series-title":"Targeted delivery of neutralizing anti-c5 antibody to renal endothelium prevents complement-dependent tissue damage","volume":"Vol. 8","author":"Macor","year":"2017"},{"issue":"7473","key":"10.1016\/j.autrev.2022.103104_bb1185","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(66)92190-8","article-title":"The transmission of immunity from mother to young and the catabolism of immunoglobulins","volume":"288","author":"Brambell","year":"1966","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.autrev.2022.103104_bb1190","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1172\/JCI107116","article-title":"The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat","volume":"51","author":"Jones","year":"1972","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.autrev.2022.103104_bb1195","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/eji.1830150718","article-title":"Isolation and characterization of an Fc receptor from neonatal rat small intestine","volume":"15","author":"Simister","year":"1985","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103104_bb1200","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1369\/0022155417705095","article-title":"Distribution of FcRn across species and tissues","volume":"65","author":"Latvala","year":"2017","journal-title":"J Histochem Cytochem"},{"issue":"8","key":"10.1016\/j.autrev.2022.103104_bb1205","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.4049\/jimmunol.157.8.3317","article-title":"Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport","volume":"157","author":"Leach","year":"1996","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb1210","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1084\/jem.20021829","article-title":"The major histocompatibility complex\u2013related Fc receptor for IgG (FcRn) binds albumin and prolongs Its lifespan","volume":"197","author":"Chaudhury","year":"2003","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.autrev.2022.103104_bb1215","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.4049\/jimmunol.170.7.3528","article-title":"The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs","volume":"170","author":"Roopenian","year":"2003","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb1220","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.4049\/jimmunol.172.4.2021","article-title":"Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn","volume":"172","author":"Ober","year":"2004","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb1225","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/jps.20297","article-title":"Pharmacokinetic effects of 4C9, an anti-fcrn antibody, in rats: Implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions","volume":"94","author":"Getman","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.autrev.2022.103104_bb1230","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/nbt1143","article-title":"Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels","volume":"23","author":"Vaccaro","year":"2005","journal-title":"Nat Biotechnol"},{"issue":"15","key":"10.1016\/j.autrev.2022.103104_bb1235","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s00018-010-0318-6","article-title":"The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases","volume":"67","author":"Sitaru","year":"2010","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"10.1016\/j.autrev.2022.103104_bb1240","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1073\/pnas.0708960105","article-title":"Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn","volume":"105","author":"Mezo","year":"2008","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"10.1016\/j.autrev.2022.103104_bb1245","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.4049\/jimmunol.178.8.5390","article-title":"Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade","volume":"178","author":"Liu","year":"2007","journal-title":"J Immunol"},{"issue":"414","key":"10.1016\/j.autrev.2022.103104_bb1250","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.autrev.2022.103104_bb1255","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb1260","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1038\/s41598-018-23481-5","article-title":"In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor","volume":"8","author":"Seijsing","year":"2018","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.autrev.2022.103104_bb1265","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/1744-9987.12474","article-title":"Therapeutic apheresis in hematologic, autoimmune and dermatologic diseases with immunologic origin","volume":"20","author":"Bambauer","year":"2016","journal-title":"Ther Apher Dial"},{"issue":"3, Supplement","key":"10.1016\/j.autrev.2022.103104_bb1270","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: A review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103104_bb1275","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","article-title":"Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: a phase 2 randomized control trial","volume":"96","author":"Bril","year":"2021","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb1280","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IGG reduction in a first-in-human study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb1285","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am J Hematol"},{"issue":"23","key":"10.1016\/j.autrev.2022.103104_bb1290","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.autrev.2022.103104_bb1295","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.autrev.2022.103104_bb1300","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.autrev.2022.103104_bb1310","series-title":"Argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART\u2122 (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis, Argenx, Editor","year":"2021"},{"key":"10.1016\/j.autrev.2022.103104_bb1315","series-title":"UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis, U.s.G. Corporate, Editor","author":"UCB","year":"2021"},{"key":"10.1016\/j.autrev.2022.103104_bb1325","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaut.2013.12.014","article-title":"Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis","volume":"52","author":"Thiruppathi","year":"2014","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb1330","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","article-title":"Durability of the rituximab response in acetylcholine receptor autoantibody\u2013positive myasthenia gravis","volume":"74","author":"Robeson","year":"2017","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb1335","first-page":"241","article-title":"Efficacy of rituximab in refractory generalized anti-AChR myasthenia gravis","volume":"5","author":"Landon-Cardinal","year":"2018","journal-title":"J Neuromusuclar Disorders"},{"issue":"5","key":"10.1016\/j.autrev.2022.103104_bb1340","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb1345","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.autrev.2022.103104_bb1350","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/jnnp.2010.220475","article-title":"Use and monitoring of low dose rituximab in myasthenia gravis","volume":"82","author":"Blum","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2022.103104_bb1355","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.15973.1","article-title":"Recent advances in understanding and managing myasthenia gravis","volume":"7","author":"Jordan","year":"2018","journal-title":"F1000Research"},{"issue":"10206","key":"10.1016\/j.autrev.2022.103104_bb1360","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.autrev.2022.103104_bb1365","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s40265-020-01370-4","article-title":"Inebilizumab: first approval","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.autrev.2022.103104_bb1370","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1111\/ajt.14872","article-title":"Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody","volume":"18","author":"Ristov","year":"2018","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.autrev.2022.103104_bb1375","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.4049\/jimmunol.166.11.6893","article-title":"Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4","volume":"166","author":"Im","year":"2001","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103104_bb1380","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.coi.2010.09.010","article-title":"Targeting BAFF in autoimmunity","volume":"22","author":"Davidson","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.autrev.2022.103104_bb1385","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2013.07.1536","article-title":"Baff (B cell activating factor) can be the clinical marker in myasthenia gravis","volume":"333","author":"Sakai","year":"2013","journal-title":"J Neurol Sci"},{"issue":"16","key":"10.1016\/j.autrev.2022.103104_bb1390","doi-asserted-by":"crossref","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2022.103104_bb1395","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577634","article-title":"High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis","volume":"358","author":"Uzawa","year":"2021","journal-title":"J Neuroimmunol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb1400","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaut.2010.12.001","article-title":"Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis","volume":"36","author":"Aricha","year":"2011","journal-title":"J Autoimmun"},{"issue":"6","key":"10.1016\/j.autrev.2022.103104_bb1405","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.nmd.2017.03.007","article-title":"Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab","volume":"27","author":"Jonsson","year":"2017","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb1410","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1749-6632.2012.06824.x","article-title":"Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?","volume":"1274","author":"Gomez","year":"2012","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb1415","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1152\/physrev.00027.2001","article-title":"The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction","volume":"82","author":"Glickman","year":"2002","journal-title":"Physiol Rev"},{"key":"10.1016\/j.autrev.2022.103104_bb1420","series-title":"International Review of Cell and Molecular Biology","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1937-6448(08)00602-3","article-title":"Role of proteasomes in cellular regulation","author":"Konstantinova","year":"2008"},{"issue":"12","key":"10.1016\/j.autrev.2022.103104_bb1425","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1002\/eji.201040620","article-title":"Immunoproteasomes are essential for survival and expansion of T cells in virus-infected mice","volume":"40","author":"Moebius","year":"2010","journal-title":"Eur J Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2022.103104_bb1430","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.4049\/jimmunol.1201183","article-title":"Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation","volume":"189","author":"Kalim","year":"2012","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2022.103104_bb1435","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/jlb.56.5.571","article-title":"Role of proteasomes modified by interferon-\u03b3 in antigen processing","volume":"56","author":"Tanaka","year":"1994","journal-title":"J Leukoc Biol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103104_bb1440","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/jcmm.12279","article-title":"Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma","volume":"18","author":"Kubiczkova","year":"2014","journal-title":"J Cell Mol Med"},{"issue":"5","key":"10.1016\/j.autrev.2022.103104_bb1445","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.cell.2013.01.037","article-title":"Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins","volume":"152","author":"Nathan","year":"2013","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.autrev.2022.103104_bb1450","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","article-title":"United states food and drug administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy","volume":"12","author":"Kane","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.autrev.2022.103104_bb1455","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth759","article-title":"Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib","volume":"2","author":"Berkers","year":"2005","journal-title":"Nat Methods"},{"key":"10.1016\/j.autrev.2022.103104_bb1460","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb1465","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/bloodadvances.2016001412","article-title":"Bortezomib-based antibody depletion for refractory autoimmune hematological diseases","volume":"1","author":"Ratnasingam","year":"2016","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb1470","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/WNL.0000000000003536","article-title":"Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis","volume":"88","author":"Scheibe","year":"2017","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.autrev.2022.103104_bb1475","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1177\/0961203317691371","article-title":"Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases","volume":"26","author":"Sj\u00f6wall","year":"2017","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/j.autrev.2022.103104_bb1480","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb1485","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.4049\/jimmunol.1301555","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients","volume":"193","author":"Gomez","year":"2014","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb1490","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.4049\/jimmunol.1002539","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis","volume":"186","author":"Gomez","year":"2011","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2022.103104_bb1495","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3109\/10428194.2010.483303","article-title":"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies","volume":"51","author":"Cavaletti","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.autrev.2022.103104_bb1500","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1177\/1060028013503122","article-title":"Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences","volume":"47","author":"Barbee","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"Supplement_1","key":"10.1016\/j.autrev.2022.103104_bb1505","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1182\/blood-2019-130847","article-title":"Mechanisms of proteasome inhibitor resistance selected by clonal evolution in multiple myeloma","volume":"134","author":"Haertle","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb1510","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-015-0529-1","article-title":"Proteasome inhibitors as experimental therapeutics of autoimmune diseases","volume":"17","author":"Verbrugge","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"16","key":"10.1016\/j.autrev.2022.103104_bb1515","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","article-title":"<em>In vitro<\/em> and <em>In Vivo<\/em> selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells","volume":"17","author":"Chauhan","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.autrev.2022.103104_bb1520","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.autrev.2022.103104_bb1525","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40262-017-0526-4","article-title":"Population pharmacokinetic analysis of ixazomib, an oral proteasome inhibitor, including data from the phase III TOURMALINE-MM1 study to inform labelling","volume":"56","author":"Gupta","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"10.1016\/j.autrev.2022.103104_bb1530","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/17474086.2018.1518129","article-title":"Ixazomib: a novel drug for multiple myeloma","volume":"11","author":"Zanwar","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.autrev.2022.103104_bb1535","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2147\/OTT.S49187","article-title":"An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma","volume":"7","author":"Offidani","year":"2014","journal-title":"Onco Targets Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2022.103104_bb1540","first-page":"A21","article-title":"48 Ixazomib, an oral proteasome inhibitor, reduces antibody production by depleting plasma cells in a t cell dependent antigen response model","volume":"4","author":"Itomi","year":"2017","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2022.103104_bb1545","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nm.1978","article-title":"A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis","volume":"15","author":"Muchamuel","year":"2009","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb1550","doi-asserted-by":"crossref","first-page":"634","DOI":"10.4049\/jimmunol.0903182","article-title":"Prevention of experimental colitis by a selective inhibitor of the immunoproteasome","volume":"185","author":"Basler","year":"2010","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb1555","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/emmm.201303543","article-title":"Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis","volume":"6","author":"Basler","year":"2014","journal-title":"EMBO Mol Med"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb1560","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/art.33333","article-title":"Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells","volume":"64","author":"Ichikawa","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb1565","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2249.2012.04578.x","article-title":"Prophylactic and therapeutic efficacies of a selective inhibitor of the immunoproteasome for Hashimoto's thyroiditis, but not for Graves' hyperthyroidism, in mice","volume":"168","author":"Nagayama","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2022.103104_bb1570","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jneuroim.2017.08.005","article-title":"ONX-0914, a selective inhibitor of immunoproteasome, ameliorates experimental autoimmune myasthenia gravis by modulating humoral response","volume":"311","author":"Liu","year":"2017","journal-title":"J Neuroimmunol"},{"issue":"13","key":"10.1016\/j.autrev.2022.103104_bb1575","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2174\/138945012803530053","article-title":"Proteasome inhibitors: A new perspective for treating autoimmune diseases","volume":"13","author":"Alessandra","year":"2012","journal-title":"Curr Drug Targets"},{"issue":"11","key":"10.1016\/j.autrev.2022.103104_bb1580","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.biochi.2010.06.023","article-title":"Proteasome inhibitors: Dozens of molecules and still counting","volume":"92","author":"de Bettignies","year":"2010","journal-title":"Biochimie"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb1585","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11302-006-9002-6","article-title":"The CD38\/CD157 mammalian gene family: An evolutionary paradigm for other leukocyte surface enzymes","volume":"2","author":"Deaglio","year":"2006","journal-title":"Purinergic Signal"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb1590","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0167-5699(94)90148-1","article-title":"Human CD38: a glycoprotein in search of a function","volume":"15","author":"Malavasi","year":"1994","journal-title":"Immunol Today"},{"issue":"9","key":"10.1016\/j.autrev.2022.103104_bb1595","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/intimm\/dxg111","article-title":"Death of T cell precursors in the human thymus: a role for CD38","volume":"15","author":"Tenca","year":"2003","journal-title":"Int Immunol"},{"issue":"13","key":"10.1016\/j.autrev.2022.103104_bb1600","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb1605","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13075-018-1578-z","article-title":"Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus","volume":"20","author":"Cole","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb1610","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol Rev"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb1615","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/jpet.119.256602","article-title":"A reduction in B, T, and natural killer cells expressing CD38 by TAK-079 inhibits the induction and progression of collagen-induced arthritis in cynomolgus monkeys","volume":"370","author":"Korver","year":"2019","journal-title":"J Pharmacol Exp Therap"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb1620","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1309\/617DWB5GNFWXHW4L","article-title":"CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms","volume":"121","author":"O\u2019Connell","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.autrev.2022.103104_bb1625","series-title":"ASH Annual Meeting Abstracts, Blood, Editor","article-title":"Indatuximab ravtansine (BT062) in combination with lenalidomide and low-dose dexamethasone in patients with relapsed and\/or refractory multiple myeloma: clinical activity in patients already exposed to lenalidomide and bortezomib","author":"Kelly","year":"2014"},{"issue":"21","key":"10.1016\/j.autrev.2022.103104_bb1630","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood.V118.21.305.305","article-title":"BT062, an antibody-drug conjugate directed against CD138, shows clinical activity in patients with relapsed or relapsed\/refractory multiple myeloma","volume":"118","author":"Jagannath","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.autrev.2022.103104_bb1635","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1158\/1078-0432.CCR-08-2867","article-title":"The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells <em>In vitro<\/em> and <em>In vivo<\/em>","volume":"15","author":"Ikeda","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb1640","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood-2006-04-015958","article-title":"Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL","volume":"109","author":"Chiu","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb1645","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells","volume":"112","author":"Avery","year":"2003","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb1650","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O'Connor","year":"2004","journal-title":"J Exp Med"},{"issue":"9","key":"10.1016\/j.autrev.2022.103104_bb1655","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.4049\/jimmunol.178.9.5612","article-title":"Divergent effects of BAFF on human memory B cell differentiation into Ig-secreting cells","volume":"178","author":"Darce","year":"2007","journal-title":"J Immunol"},{"issue":"20","key":"10.1016\/j.autrev.2022.103104_bb1660","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti\u2013B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.autrev.2022.103104_bb1665","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.autrev.2022.103104_bb1670","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt.15.77","article-title":"Targeting B-cell maturation antigen in multiple myeloma","volume":"7","author":"Tai","year":"2015","journal-title":"Immunotherapy"},{"issue":"1821","key":"10.1016\/j.autrev.2022.103104_bb1675","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: Potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb1680","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody\u2013drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J"},{"issue":"13","key":"10.1016\/j.autrev.2022.103104_bb1685","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.autrev.2022.103104_bb1690","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/s41375-020-0951-5","article-title":"Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma","volume":"35","author":"Lin","year":"2021","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.autrev.2022.103104_bb1695","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.autrev.2022.103104_bb1700","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.autrev.2022.103104_bb1705","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.autrev.2022.103104_bb1710","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2022.103104_bb1715","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.4049\/jimmunol.170.6.3392","article-title":"Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus","volume":"170","author":"Balabanian","year":"2003","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2022.103104_bb1720","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.4049\/jimmunol.0801920","article-title":"CXCR4\/CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus","volume":"182","author":"Wang","year":"2009","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2022.103104_bb1725","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.4049\/jimmunol.167.8.4686","article-title":"AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-\u03b3 receptor-deficient mice","volume":"167","author":"Matthys","year":"2001","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb1730","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/toxsci\/kfn105","article-title":"Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept","volume":"105","author":"Carbonatto","year":"2008","journal-title":"Toxicol Sci"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb1735","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1186\/ar2959","article-title":"B-lymphocyte stimulator\/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin","volume":"12","author":"Dillon","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.autrev.2022.103104_bb1740","article-title":"Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme","volume":"3","author":"Gordon","year":"2019","journal-title":"Rheumatol Adv Pract"},{"issue":"1","key":"10.1016\/j.autrev.2022.103104_bb1745","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4049\/jimmunol.180.1.361","article-title":"Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice","volume":"180","author":"DiLillo","year":"2008","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2022.103104_bb1750","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/eji.201847492","article-title":"Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors","volume":"48","author":"Alexander","year":"2018","journal-title":"Eur J Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2022.103104_bb1755","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135081","article-title":"Bortezomib plus continuous B cell depletion results in sustained plasma cell depletion and amelioration of lupus nephritis in NZB\/W F1 mice","volume":"10","author":"Khodadadi","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.autrev.2022.103104_bb1760","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/1756285617721093","article-title":"Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience","volume":"10","author":"Schneider-Gold","year":"2017","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722200074X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722200074X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:26:08Z","timestamp":1761600368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899722200074X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":349,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S156899722200074X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103104","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103104","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103104"}}